

## **Additional file 2: List of excluded studies**

### **Studies by each reason for exclusion.**

#### **Reason for exclusion, population (n=3)**

BARTOLOMEO, N., TREROTOLI, P. & SERIO, G. 2011. Progression of liver cirrhosis to HCC: an application of hidden Markov model. *BMC Med Res Methodol*, 11, 38.

PEREZ, R. U., CASTILLO MUNOZ, M. A., NAVARRO CABALLERO, J. A. & MARQUEZ PELAEZ, S. 2012. Inhibidores de la proteasa (boceprevir y telaprevir) en el tratamiento de pacientes mono infectados por el VHC: eficacia, seguridad y eficiencia comparada [Protease inhibitors (Boceprevir and telaprevir) in the treatment of chronic HCV infection: relative efficacy, safety and efficiency]. York (UK): CRD York HTA Database.

THOMPSON COON, J., ROGERS, G., HEWSON, P., WRIGHT, D., ANDERSON, R., JACKSON, S., RYDER, S., CRAMP, M. & STEIN, K. 2008. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. *Br J Cancer*, 98, 1166-75.

#### **Reason for exclusion, intervention (n=127)**

ANNEMANS, L., WARIE, H., NECHELPUT, M. & PERAUX, B. 2004. A health economic model to assess the long term effects and cost-effectiveness of PEG IFN alpha-2a in hepatitis C virus infected patients. *Acta Gastroenterol Belg*, 67, 1-8.

BARROS, F. M., CHEINQUER, H., TSUCHIYA, C. T. & SANTOS, E. A. 2013. Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil. *Cost Eff Resour Alloc*, 11, 25.

BENNETT, W. G., INOUE, Y., BECK, J. R., WONG, J. B., PAUKER, S. G. & DAVIS, G. L. 1997. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. *Ann Intern Med*, 127, 855-65.

BERNFORT, L., SENNFALT, K. & REICHARD, O. 2006. Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden. *Scand J Infect Dis*, 38, 497-505.

BLATT, C. R., STORB, B., MUHLBERGER, N., FARIAS, M. R. & SIEBERT, U. 2014. Chronic hepatitis C treatment for genotype 2 or 3 in Brazil: cost effectiveness analysis of peginterferon plus ribavirin as first choice treatment. *Brazilian Journal of Pharmaceutical Sciences*, 50, 345-352.

BOCK, J. A., FAIRLEY, K. J., SMITH, R. E., MAENG, D. D., PITCAVAGE, J. M., INVERSO, N. A. & WILLIAMS, M. S. 2014. Cost-effectiveness of IL28Beta genotype-guided protease inhibitor triple therapy versus standard of care treatment in patients with hepatitis C genotypes 2 or 3 infection. *Public Health Genomics*, 17, 306-19.

BUTI, M., CASADO, M. A. & ESTEBAN, R. 2007. Evaluating the cost of sustained virologic response in naive chronic hepatitis C patients treated a la carte. *Aliment Pharmacol Ther*, 26, 705-16.

- BUTI, M., CASADO, M. A., FOSBROOK, L. & ESTEBAN, R. 2002. Which is the most cost effective combination therapy strategy using interferon alpha-2b plus ribavirin for naive patients with chronic hepatitis C? *Clinical Drug Investigation*, 22, 31-39.
- BUTI, M., CASADO, M. A., FOSBROOK, L. & ESTEBAN, R. 2005. Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1. *Pharmacoeconomics*, 23, 1043-55.
- BUTI, M., CASADO, M. A., FOSBROOK, L., WONG, J. B. & ESTEBAN, R. 2000. Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C. *J Hepatol*, 33, 651-8.
- BUTI, M., MEDINA, M., CASADO, M. A., WONG, J. B., FOSBROOK, L. & ESTEBAN, R. 2003. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. *Aliment Pharmacol Ther*, 17, 687-94.
- DAVIS, G. L., BECK, J. R., FARRELL, G. & POYNARD, T. 1998. Prolonged treatment with interferon in patients with histologically mild chronic hepatitis C: a decision analysis. *J Viral Hepat*, 5, 313-21.
- DEUFFIC-BURBAN, S., BABANY, G., LONJON-DOMANEC, I., DELTENRE, P., CANVA-DELCAMBRE, V., DHARANCY, S., LOUVET, A., ROUDOT-THORAVAL, F. & MATHURIN, P. 2009. Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France. *Hepatology*, 50, 1351-9.
- DEUFFIC-BURBAN, S., DELTENRE, P., BUTI, M., STROFFOLINI, T., PARKES, J., MUHLBERGER, N., SIEBERT, U., MORENO, C., HATZAKIS, A., ROSENBERG, W., ZEUZEM, S. & MATHURIN, P. 2012. Predicted effects of treatment for HCV infection vary among European countries. *Gastroenterology*, 143, 974-85 e14.
- DOLDER, N. M., WILHARDT, M. S. & MORREALE, A. P. 2002. Justifying a multidisciplinary high-intensity hepatitis C clinic by using decision analysis. *Am J Health Syst Pharm*, 59, 867-71.
- DUSHEIKO, G. M. & ROBERTS, J. A. 1995. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. *Hepatology*, 22, 1863-73.
- EL HOUBY, E. M. 2014. A framework for prediction of response to HCV therapy using different data mining techniques. *Adv Bioinformatics*, 2014, 181056.
- EL SAADANY, S., COYLE, D., GIULIVI, A. & AFZAL, M. 2005. Economic burden of hepatitis C in Canada and the potential impact of prevention. Results from a disease model. *Eur J Health Econ*, 6, 159-65.
- FONSECA, M. C., ARAUJO, G. T. & ARAUJO, D. V. 2009. Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil. *Braz J Infect Dis*, 13, 191-9.
- GARCIA DE ANCOS, J. L., ROBERTS, J. A. & DUSHEIKO, G. M. 1990. An economic evaluation of the costs of alpha-interferon treatment of chronic active hepatitis due to hepatitis B or C virus. *J Hepatol*, 11 Suppl 1, S11-8.

- GARCIA-CONTRERAS, F., NEVAREZ-SIDA, A., CONSTANTINO-CASAS, P., ABUD-BASTIDA, F. & GARDUNO-ESPINOSA, J. 2006. Cost-effectiveness of chronic hepatitis C treatment with thymosin alpha-1. *Arch Med Res*, 37, 663-73.
- GELLAD, Z. F., MUIR, A. J., MCHUTCHISON, J. G., SIEVERT, W., SHARARA, A. I., BROWN, K. A., FLISIAK, R., JACOBSON, I. M., KERSHENOBICH, D., MANNS, M. P., SCHULMAN, K. A. & REED, S. D. 2012. Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response. *Value Health*, 15, 876-86.
- GERKENS, S., NECHELPUT, M., ANNEMANS, L., PERAUX, B., BEGUIN, C. & HORMANS, Y. 2007. A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels. *Acta Gastroenterol Belg*, 70, 177-87.
- GERKENS, S., NECHELPUT, M., ANNEMANS, L., PERAUX, B., MOUCHART, M., BEGUIN, C. & HORMANS, Y. 2007. A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C. *J Viral Hepat*, 14, 523-36.
- GHEORGHE, L. & BACULEA, S. 2010. Cost-effectiveness of peginterferon alpha-2a and peginterferon alpha-2b combination regimens in genotype-1 naive patients with chronic hepatitis C. *Hepatogastroenterology*, 57, 939-44.
- GORDON, S. C., POCKROS, P. J., TERRAULT, N. A., HOOP, R. S., BUIKEMA, A., NERENZ, D. & HAMZEH, F. M. 2012. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. *Hepatology*, 56, 1651-60.
- GRIEVE, R. & ROBERTS, J. 2002. Economic evaluation for hepatitis C. *Acta Gastroenterol Belg*, 65, 104-9.
- GRIEVE, R., ROBERTS, J., WRIGHT, M., SWEETING, M., DE ANGELIS, D., ROSENBERG, W., BASSENDINE, M., MAIN, J. & THOMAS, H. 2006. Cost effectiveness of interferon A or peginterferon A with ribavirin for histologically mild chronic hepatitis C (Structured Abstract). *Gut*, 55.
- GRIEVE, R., ROBERTS, J., WRIGHT, M., SWEETING, M., DEANGELIS, D., ROSENBERG, W., BASSENDINE, M., MAIN, J. & THOMAS, H. 2006. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. *Gut*, 55, 1332-8.
- GRISHCHENKO, M., GRIEVE, R. D., SWEETING, M. J., DE ANGELIS, D., THOMSON, B. J., RYDER, S. D., IRVING, W. L. & TRENT, H. C. V. S. G. 2009. Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. *Int J Technol Assess Health Care*, 25, 171-80.
- GUENKA, P., ASSENA, S. & MANOVA, M. 2009. Cost-effectiveness of peginterferon alfa-2b) in HCV infection: A Bulgarian Scenario. *Archives of the Balkan Medical Union*, 44, 215-219.
- GURUSAMY, K. S., WILSON, E., KORETZ, R. L., ALLEN, V. B., DAVIDSON, B. R., BURROUGHS, A. K. & GLUUD, C. 2013. Is sustained virological response a marker of treatment efficacy in patients with chronic hepatitis C viral infection with no response or relapse to previous antiviral intervention? *PLoS One*, 8, e83313.

- HAGAN, L. M., YANG, Z., EHTESHAMI, M. & SCHINAZI, R. F. 2013. All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. *J Viral Hepat*, 20, 847-57.
- HARTWELL, D., COOPER, K., FRAMPTON, G. K., BAXTER, L. & LOVEMAN, E. 2014. The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation. *Health Technol Assess*, 18, i-xxii, 1-202.
- HARTWELL, D., JONES, J., BAXTER, L. & SHEPHERD, J. 2011. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. *Health Technol Assess*, 15, i-xii, 1-210.
- HAYASHIDA, K., NAGASUE, I., FUKUDA, T. & GUNJI, A. 2002. The natural history model of hepatitis C virus infection and the economic evaluation of alpha interferon treatment. *J Epidemiol*, 12, 22-32.
- HORNBERGER, J., FARCI, P., PRATI, D., ZEUZEM, S., GREEN, J. & PATEL, K. K. 2006. The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase. *J Viral Hepat*, 13, 377-86.
- HORNBERGER, J., TORRIANI, F. J., DIETERICH, D. T., BRAU, N., SULKOWSKI, M. S., TORRES, M. R., GREEN, J. & PATEL, K. 2006. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. *J Clin Virol*, 36, 283-91.
- HOSHIDA, Y., SHIRATORI, Y. & OMATA, M. 2002. Cost-effectiveness of adjuvant interferon therapy after surgical resection of Hepatitis C-related hepatocellular carcinoma. *Liver*, 22, 479-85.
- HUANG, T., TU, K., SHYR, Y., WEI, C. C., XIE, L. & LI, Y. X. 2008. The prediction of interferon treatment effects based on time series microarray gene expression profiles. *J Transl Med*, 6, 44.
- IANNAZZO, S., COLOMBATTO, P., RICCO, G., OLIVERI, F., BONINO, F. & BRUNETTO, M. R. 2015. A cost-effectiveness model to personalize antiviral therapy in naive patients with genotype 1 chronic hepatitis C. *Dig Liver Dis*, 47, 249-54.
- IKEDA, K., KAWAMURA, Y., KOBAYASHI, M., FUKUSHIMA, T., SEZAKI, H., HOSAKA, T., AKUTA, N., SAITOH, S., SUZUKI, F., SUZUKI, Y., ARASE, Y. & KUMADA, H. 2014. Prevention of disease progression with anti-inflammatory therapy in patients with HCV-related cirrhosis: a Markov model. *Oncology*, 86, 295-302.
- INNES, H., GOLDBERG, D., DUSHEIKO, G., HAYES, P., MILLS, P. R., DILLON, J. F., ASPINALL, E., BARCLAY, S. T. & HUTCHINSON, S. J. 2014. Patient-important benefits of clearing the hepatitis C virus through treatment: a simulation model. *J Hepatol*, 60, 1118-26.
- ISHIDA, H., INOUE, Y., WONG, J. B. & OKITA, K. 2004. Cost-effectiveness of ribavirin plus interferon alpha-2b for either interferon relapsers or non-responders in chronic hepatitis C: a Japanese trial. *Hepatol Res*, 28, 125-136.
- KIM, D. D., HUTTON, D. W., RAOUF, A. A., SALAMA, M., HABLAS, A., SEIFELDIN, I. A. & SOLIMAN, A. S. 2015. Cost-effectiveness model for hepatitis C screening and

treatment: Implications for Egypt and other countries with high prevalence. *Glob Public Health*, 10, 296-317.

KIM, W. R., POTERUCHA, J. J., HERMANS, J. E., THERNEAU, T. M., DICKSON, E. R., EVANS, R. W. & GROSS, J. B., JR. 1997. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. *Ann Intern Med*, 127, 866-74.

KRAHN, M. D., JOHN-BAPTISTE, A., YI, Q., DORIA, A., REMIS, R. S., RITVO, P. & FRIEDMAN, S. 2005. Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada. *Vaccine*, 23, 1549-58.

KUEHNE, F. C., BETHE, U., FREEDBERG, K. & GOLDIE, S. J. 2002. Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness. *Arch Intern Med*, 162, 2545-56.

KUROSAKI, M., HIRAMATSU, N., SAKAMOTO, M., SUZUKI, Y., IWASAKI, M., TAMORI, A., MATSUURA, K., KAKINUMA, S., SUGAUCHI, F., SAKAMOTO, N., NAKAGAWA, M., YATSUHASHI, H. & IZUMI, N. 2012. Age and total ribavirin dose are independent predictors of relapse after interferon therapy in chronic hepatitis C revealed by data mining analysis. *Antivir Ther*, 17, 35-43.

KUROSAKI, M., MATSUNAGA, K., HIRAYAMA, I., TANAKA, T., SATO, M., YASUI, Y., TAMAKI, N., HOSOKAWA, T., UEDA, K., TSUCHIYA, K., NAKANISHI, H., IKEDA, H., ITAKURA, J., TAKAHASHI, Y., ASAHINA, Y., HIGAKI, M., ENOMOTO, N. & IZUMI, N. 2010. A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. *Hepatol Res*, 40, 251-60.

KUROSAKI, M., SAKAMOTO, N., IWASAKI, M., SAKAMOTO, M., SUZUKI, Y., HIRAMATSU, N., SUGAUCHI, F., TAMORI, A., NAKAGAWA, M. & IZUMI, N. 2011. Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis. *J Med Virol*, 83, 445-52.

KUROSAKI, M., SAKAMOTO, N., IWASAKI, M., SAKAMOTO, M., SUZUKI, Y., HIRAMATSU, N., SUGAUCHI, F., YATSUHASHI, H. & IZUMI, N. 2011. Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis. *J Gastroenterol*, 46, 401-9.

LIDGREN, M., HOLLANDER, A., WEILAND, O. & JONSSON, B. 2007. Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life. *Scand J Gastroenterol*, 42, 867-77.

LIN, W. A., TARN, Y. H. & TANG, S. L. 2006. Cost-utility analysis of different peg-interferon alpha-2b plus ribavirin treatment strategies as initial therapy for naive Chinese patients with chronic hepatitis C. *Aliment Pharmacol Ther*, 24, 1483-93.

LOGGE, C., VETTORAZZI, E., FISCHER, L., NASHAN, B. & STERNECK, M. 2013. Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection. *Transpl Int*, 26, 527-34.

MALONE, D. C., TRAN, T. T. & POORDAD, F. F. 2005. Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C. *J Manag Care Pharm*, 11, 687-94.

MANDRIK, O., KNIES, S., GOLUBOVSKA, O., DUDA, O., DUDAR, L., FEDORCHENKO, S., ZALISKA, O. & HANS SEVERENS, J. L. 2015. Cost comparison

of treating chronic hepatitis C genotype one with pegylated interferons in Ukraine. *Open Med (Wars)*, 10, 25-33.

MARTIN, N. K., PITCHER, A. B., VICKERMAN, P., VASSALL, A. & HICKMAN, M. 2011. Optimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug users. *PLoS One*, 6, e22309.

MARTIN, N. K., VICKERMAN, P., FOSTER, G. R., MINERS, A., HUTCHINSON, S. J., GOLDBERG, D. & HICKMAN, M. 2011. The cost-effectiveness of HCV antiviral treatment for injecting drug user populations. *Gut*, 60, A25.

MARTIN, N. K., VICKERMAN, P., MINERS, A., FOSTER, G. R., HUTCHINSON, S. J., GOLDBERG, D. J. & HICKMAN, M. 2012. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. *Hepatology*, 55, 49-57.

MCEWAN, P., KIM, R. & YUAN, Y. 2013. Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model. *Appl Health Econ Health Policy*, 11, 53-63.

MEHRAZMAY, A., ALAVIAN, S. M., MORADI-LAKEH, M., MOKHTARI PAYAM, M., HASHEMI-MESHKINI, A., BEHNAVA, B., MIRI, S. M., KARIMI ELIZEE, P., TABATABAEE, S. V., KESHVARI, M. & BAGHERI LANKARANI, K. 2013. Cost-effectiveness analysis of adding low dose ribavirin to peginterferon alfa-2a for treatment of chronic hepatitis C infected thalassemia major patients in iran. *Hepat Mon*, 13, e10236.

MENNINI, F. S., MARCELLUSI, A., ANDREONI, M., GASBARRINI, A., SALOMONE, S. & CRAXI, A. 2014. Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy. *Clinicoecon Outcomes Res*, 6, 303-10.

MESSORI, A., FADDA, V., MARATEA, D. & TRIPPOLI, S. 2012. Effect of discounting on estimation of benefits determined by hepatitis C treatment. *World J Gastroenterol*, 18, 3032-4.

MINERS, A. H., MARTIN, N. K., GHOSH, A., HICKMAN, M. & VICKERMAN, P. 2014. Assessing the cost-effectiveness of finding cases of hepatitis C infection in UK migrant populations and the value of further research. *J Viral Hepat*, 21, 616-23.

MORIGUCHI, H., UEMURA, T., KOBAYASHI, M., CHUNG, R. T. & SATO, C. 2002. Management strategies using pharmacogenomics in patients with severe HCV-1b infection: a decision analysis. *Hepatology*, 36, 177-85.

MOSEGUI, G. B. G., VIANNA, C. M. D. M., RODRIGUES, M. P. D. S. & PEREZ, R. D. M. 2011. Alfapeguinterferon-2a e ribavirina versus alfapeguinterferon-2b e ribavirina: avaliação custo-efetividade e do impacto orçamentário do tratamento do genótipo 1 da hepatite C crônica. *Physis: Revista de Saúde Coletiva*, 21, 377-393.

MOURAD, A., DEUFFIC-BURBAN, S., GANNE-CARRIE, N., RENAUT-VANTROYS, T., ROSA, I., BOUVIER, A. M., LAUNOY, G., CATTAN, S., LOUVET, A., DHARANCY, S., TRINCHET, J. C., YAZDANPANAH, Y. & MATHURIN, P. 2014. Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: a modeling approach. *Hepatology*, 59, 1471-81.

- MUNARI, L. M. & PICCIOTTO, A. 1996. Recombinant interferon alpha2b therapy of chronic hepatitis C in Italy: An economic analysis. *FORUM - Trends in Experimental and Clinical Medicine*, 6, 347-353.
- NAKAMURA, J., KOBAYASHI, K., TOYABE, S., AOYAGI, Y. & AKAZAWA, K. 2007. The cost-effectiveness of the new protocol reflecting rapid virologic response to peginterferon alpha-2b and ribavirin for chronic hepatitis C. *Eur J Gastroenterol Hepatol*, 19, 733-9.
- NAKAMURA, J., TOYABE, S. I., AOYAGI, Y. & AKAZAWA, K. 2008. Economic impact of extended treatment with peginterferon alpha-2a and ribavirin for slow hepatitis C virologic responders. *J Viral Hepat*, 15, 293-9.
- OBACH, D., DEUFFIC-BURBAN, S., ESMAT, G., ANWAR, W. A., DEWEDAR, S., CANVA, V., COUSIEN, A., DOSS, W., MOSTAFA, A., POL, S., BUTI, M., SIEBERT, U., FONTANET, A., MOHAMED, M. K. & YAZDANPANAHI, Y. 2014. Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt. *Clin Infect Dis*, 58, 1064-71.
- PATEL, D., TERRAULT, N. A., YAO, F. Y., BASS, N. M. & LADABAUM, U. 2005. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. *Clin Gastroenterol Hepatol*, 3, 75-84.
- POKORSKI, R. J. 2000. Long-term insured lives morbidity and mortality risk associated with chronic hepatitis C virus infection. *J Insur Med*, 32, 226-48.
- POKORSKI, R. J. 2001. Long-term morbidity and mortality risk in Japanese insurance applicants with chronic hepatitis C virus infection. *J Insur Med*, 33, 12-36.
- RAVASIO, R. 2008. [Cost-effectiveness of peginterferon alpha-2a plus ribavirin versus peginterferon alpha-2b plus ribavirin in the treatment of chronic hepatitis C in HIV-HCV co-infection]. *Pharmacoeconomics Italian Research Articles*, 10, 37-47.
- RAVASIO, R., SACCHI, P., MAIOCCHI, L., PATRUNO, S., BRUNO, R. & FILICE, G. 2005. Costo efficacia di peginterferone  $\alpha$ -2a + ribavirina verso peginterferone  $\alpha$ -2b + ribavirina nel trattamento dell'epatite cronica di tipo C in pazienti non pretrattati. *Pharmacoeconomics Italian Research Articles*, 7, 207-218.
- ROBERTS, J. A. 1999. The economic aspects of hepatitis C-- implications for haemophilia. *Haemophilia*, 5, 402-9.
- RODRIGUES, M. P., VIANNA, C. M., MOSEGUI, G. B., COSTA E SILVA, F. V., PEREGRINO, A. A. & JARDIM, F. N. 2013. [Cost-effectiveness of hepatitis C treatment in slow virologic responders coinfecting with HIV]. *Cad Saude Publica*, 29 Suppl 1, S146-58.
- SAAB, S., HUNT, D. R., STONE, M. A., MCCLUNE, A. & TONG, M. J. 2010. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. *Liver Transpl*, 16, 748-59.
- SACKS-DAVIS, R., MCBRYDE, E., GREBELY, J., HELLARD, M. & VICKERMAN, P. 2015. Many hepatitis C reinfections that spontaneously clear may be undetected: Markov-chain Monte Carlo analysis of observational study data. *J R Soc Interface*, 12, 20141197.

- SAGMEISTER, M., WONG, J. B., MULLHAUPT, B. & RENNER, E. L. 2001. A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C. *Eur J Gastroenterol Hepatol*, 13, 483-8.
- SALOMON, J. A., WEINSTEIN, M. C., HAMMITT, J. K. & GOLDIE, S. J. 2003. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. *JAMA*, 290, 228-37.
- SAN MIGUEL, R., MAR, J., CABASES, J. M., GUILLEN-GRIMA, F. & BUTI, M. 2003. Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon. *Aliment Pharmacol Ther*, 17, 765-73.
- SENNFALT, K., REICHARD, O., HULTKRANTZ, R., WONG, J. B. & JONSSON, D. 2001. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden. *Scand J Gastroenterol*, 36, 870-6.
- SHEPHERD, J., BRODIN, H., CAVE, C., WAUGH, N., PRICE, A. & GABBAY, J. 2004. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. *Health Technol Assess*, 8, iii-iv, 1-125.
- SHEPHERD, J., BRODIN, H. F., CAVE, C. B., WAUGH, N. R., PRICE, A. & GABBAY, J. 2005. Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation. *Int J Technol Assess Health Care*, 21, 47-54.
- SHEPHERD, J. & JONES, J. 2007. A systematic review of the cost-effectiveness of peginterferon alfa-2b in the treatment of chronic hepatitis C. *Expert Rev Pharmacoecon Outcomes Res*, 7, 577-95.
- SHEPHERD, J., JONES, J., HARTWELL, D., DAVIDSON, P., PRICE, A. & WAUGH, N. 2007. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. *Health Technol Assess*, 11, 1-205, iii.
- SHEPHERD, J., WAUGH, N. & HEWITSON, P. 2000. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. *Health Technol Assess*, 4, 1-67.
- SHIELL, A., BRIGGS, A. & FARRELL, G. C. 1994. The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C. *Med J Aust*, 160, 268-72.
- SHIELL, A., BROWN, S. & FARRELL, G. C. 1999. Hepatitis C: an economic evaluation of extended treatment with interferon. *Med J Aust*, 171, 189-93.
- SIEBERT, U. & SROCZYNSKI, G. 2003. Antiviral therapy for patients with chronic hepatitis C in Germany - evaluation of effectiveness and cost effectiveness of initial combination therapy with interferon / peginterferon plus ribavirin (structured abstract) HTA-3200500570. York (UK): CRD YORK HTA Database.
- SIEBERT, U., SROCZYNSKI, G., AIDELSBURGER, P., ROSSOL, S., WASEM, J., MANN, M. P., MCHUTCHISON, J. G. & WONG, J. B. 2009. Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines. *Pharmacoeconomics*, 27, 341-54.



SIEBERT, U., SROCZYNSKI, G., GERMAN HEPATITIS, C. M. G. & C, H. T. A. E. P. O. H. 2003. Antiviral combination therapy with interferon/peginterferon plus ribavirin for patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Agency for Health Technology Assessment. *Ger Med Sci*, 1, Doc07.

SIEBERT, U., SROCZYNSKI, G., GERMAN HEPATITIS, C. M. G. G. & C, H. T. A. E. P. O. H. 2005. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. *Int J Technol Assess Health Care*, 21, 55-65.

SIEBERT, U., SROCZYNSKI, G., ROSSOL, S., WASEM, J., RAVENS-SIEBERER, U., KURTH, B. M., MANNS, M. P., MCHUTCHISON, J. G., WONG, J. B., GERMAN HEPATITIS, C. M. G. & INTERNATIONAL HEPATITIS INTERVENTIONAL THERAPY, G. 2003. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. *Gut*, 52, 425-32.

SIMON, K., GLADYSZ, A., ROTTER, K., RYMER, W., SMOLINSKI, P., INGLLOT, M. & WLADYSIU-K-BLICHARZ, M. 2006. Cost effectiveness of replacing recombinated interferon alpha-2b with its pegylated form in combination with ribavirin for the therapy of chronic HCV infection in Poland. *Advanced in Experimental Medicine*.

SINHA, M. & DAS, A. 2000. Cost effectiveness analysis of different strategies of management of chronic hepatitis C infection in children. *Pediatr Infect Dis J*, 19, 23-30.

SNOECK, E., HADZIYANNIS, S. J., PUOTI, C., SWAIN, M. G., BERG, T., MARCELLIN, P., ZARSKI, J. P., JORGA, K. & ZEUZEM, S. 2008. Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently 'normal' alanine aminotransferase levels treated with peginterferon alpha-2a (40KD) plus ribavirin. *Liver Int*, 28, 61-71.

STEIN, K., ROSENBERG, W. & WONG, J. 2002. Cost effectiveness of combination therapy for hepatitis C: a decision analytic model. *Gut*, 50, 253-8.

SULLIVAN, S. D., CRAXI, A., ALBERTI, A., GIULIANI, G., DE CARLI, C., WINTFELD, N., PATEL, K. K. & GREEN, J. 2004. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. *Pharmacoeconomics*, 22, 257-65.

SULLIVAN, S. D., CRAXI, A., ALBERTI, A., GIULIANI, G., DE CARLI, C., WINTFELD, N., PATEL, K. K. & GREEN, J. 2004. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. *Pharmacoeconomics*, 22, 257-65.

SULLIVAN, S. D., CRAXI, A., ALBERTI, A., GIULIANI, G., DE CARLI, C., WINTFELD, N., PATEL, K. K. & GREEN, J. 2004. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. *Pharmacoeconomics Italian Research Articles*, 6, 105-114.

SULLIVAN, S. D., JENSEN, D. M., BERNSTEIN, D. E., HASSANEIN, T. I., FOSTER, G. R., LEE, S. S., CHEINQUER, H., CRAXI, A., COOKSLEY, G., KLASKALA, W., PETTIT, K., PATEL, K. K. & GREEN, J. 2004. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. *Am J Gastroenterol*, 99, 1490-6.

SWEETING, M. J., DE ANGELIS, D., NEAL, K. R., RAMSAY, M. E., IRVING, W. L., WRIGHT, M., BRANT, L., HARRIS, H. E., TRENT, H. C. V. S. G. & GROUP, H. C. V. N. R. S. 2006. Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment. *J Clin Epidemiol*, 59, 144-52.

SWEETING, M. J., FAREWELL, V. T. & DE ANGELIS, D. 2010. Multi-state Markov models for disease progression in the presence of informative examination times: an application to hepatitis C. *Stat Med*, 29, 1161-74.

TAKEDA, A., JONES, J., SHEPHERD, J., DAVIDSON, P. & PRICE, A. 2007. A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B. *J Viral Hepat*, 14, 75-88.

TERRAULT, N. A., IM, K., BOYLAN, R., BACCHETTI, P., KLEINER, D. E., FONTANA, R. J., HOOFNAGLE, J. H., BELLE, S. H. & GROUP, V.-C. S. 2008. Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C. *Clin Gastroenterol Hepatol*, 6, 1403-11.

THOMPSON COON, J., ROGERS, G., HEWSON, P., WRIGHT, D., ANDERSON, R., CRAMP, M., JACKSON, S., RYDER, S., PRICE, A. & STEIN, K. 2007. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. *Health Technol Assess*, 11, 1-206.

TURNBULL, C. & SUGANO, D. 1994. Cost effectiveness of interferon in chronic active hepatitis C. *Med J Aust*, 161, 169; author reply 170.

TURNES, J., ROMERO-GOMEZ, M., PLANAS, R., SOLA, R., GARCIA-SAMANIEGO, J., DIAGO, M., CRESPO, J., CALLEJA, J. L., RUBIO-TERRES, C. & VENTAYOL, P. 2013. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain. *Gastroenterol Hepatol*, 36, 555-64.

VACHON, M. L. & DIETERICH, D. T. 2012. A great time to invest in baby Boomer's hepatitis C! *Hepatology*, 56, 1575-7.

VAN LEEUWEN, D. J. 1999. Cost-effectiveness of interferon treatment for hepatitis C. *JAMA*, 281, 2083-4.

VISCONTI, A. J., DOYLE, J. S., WEIR, A., SHIELL, A. M. & HELLARD, M. E. 2013. Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia. *J Gastroenterol Hepatol*, 28, 707-16.

VOLK, M. L., TOCCO, R., SAINI, S. & LOK, A. S. 2009. Public health impact of antiviral therapy for hepatitis C in the United States. *Hepatology*, 50, 1750-5.

WERB, D., WOOD, E., KERR, T., HERSHFIELD, N., PALMER, R. W. & REMIS, R. S. 2011. Treatment costs of hepatitis C infection among injection drug users in Canada, 2006-2026. *Int J Drug Policy*, 22, 70-6.

WONG, J. & NEVENS, F. 2002. Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium. *Acta Gastroenterol Belg*, 65, 110-11.

WONG, J. B. 1998. Interferon treatment for chronic hepatitis B or C infection: costs and effectiveness. *Acta Gastroenterol Belg*, 61, 238-42.

WONG, J. B. 1999. Cost-effectiveness of treatments for chronic hepatitis C. *Am J Med*, 107, 74S-78S.

WONG, J. B., BENNETT, W. G., KOFF, R. S. & PAUKER, S. G. 1998. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. *JAMA*, 280, 2088-93.

WONG, J. B., DAVIS, G. L. & PAUKER, S. G. 2000. Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C. *Am J Med*, 108, 366-73.

WONG, J. B. & KOFF, R. S. 2000. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. *Ann Intern Med*, 133, 665-75.

WONG, J. B., POYNARD, T., LING, M. H., ALBRECHT, J. K. & PAUKER, S. G. 2000. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. *Am J Gastroenterol*, 95, 1524-30.

YEH, W. S., ARMSTRONG, E. P., SKREPNEK, G. H. & MALONE, D. C. 2007. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System. *Pharmacotherapy*, 27, 813-24.

YOUNOSSI, Z. M., SINGER, M. E., MCHUTCHISON, J. G. & SHERMOCK, K. M. 1999. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. *Hepatology*, 30, 1318-24.

YOUNOSSI, Z. M., SINGER, M. E., MIR, H. M., HENRY, L. & HUNT, S. 2014. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. *J Hepatol*, 60, 530-7.

#### **Reason for exclusion, outcome (n=4)**

DEUFFIC-BURBAN, S., CASTEL, H., WIEGAND, J., MANNS, M. P., WEDEMEYER, H., MATHURIN, P. & YAZDANPANA, Y. 2012. Immediate vs. delayed treatment in patients with acute hepatitis C based on IL28B polymorphism: a model-based analysis. *J Hepatol*, 57, 260-6.

ECKMAN, M. H., TALAL, A. H., GORDON, S. C., SCHIFF, E. & SHERMAN, K. E. 2013. Cost-effectiveness of screening for chronic hepatitis C infection in the United States. *Clin Infect Dis*, 56, 1382-93.

LIN, O. S., KEEFFE, E. B., SANDERS, G. D. & OWENS, D. K. 2004. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. *Aliment Pharmacol Ther*, 19, 1159-72.

MCEWAN, P., WARD, T., BENNETT, H., KALSEKAR, A., WEBSTER, S., BRENNER, M. & YUAN, Y. 2015. Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C. *PLoS One*, 10, e0117334.

#### **Reason for exclusion, study design (n=32)**

CHONG, C. A., GULAMHUSSEIN, A., HEATHCOTE, E. J., LILLY, L., SHERMAN, M., NAGLIE, G. & KRAHN, M. 2003. Health-state utilities and quality of life in hepatitis C patients. *Am J Gastroenterol*, 98, 630-8.

DORE, G. J., FREEMAN, A. J., LAW, M. & KALDOR, J. M. 2002. Is severe liver disease a common outcome for people with chronic hepatitis C? *J Gastroenterol Hepatol*, 17, 423-30.

DORE, G. J. & THEIN, H. H. 2003. Cost-effectiveness of treatment for chronic hepatitis C infection. *JAMA*, 290, 1993; author reply 1994.

GELLAD, Z. F., REED, S. D. & MUIR, A. J. 2012. Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C. *Antivir Ther*, 17, 1189-99.

HAGAN, L. 2014. Cost-effectiveness and access to care in the treatment of hepatitis C virus infection. *Gastroenterol Hepatol (N Y)*, 10, 259-61.

HARTWELL, D., JONES, J., BAXTER, L. & SHEPHERD, J. 2012. Shortened peginterferon and ribavirin treatment for chronic hepatitis C. *Int J Technol Assess Health Care*, 28, 398-406.

HASHEM, A. M., RASMY, M. E., WAHBA, K. M. & SHAKER, O. G. 2012. Single stage and multistage classification models for the prediction of liver fibrosis degree in patients with chronic hepatitis C infection. *Comput Methods Programs Biomed*, 105, 194-209.

HENLEY, E. 1999. Cost-effectiveness of interferon treatment for hepatitis C. *JAMA*, 281, 2083; author reply 2084.

JOHN-BAPTISTE, A., YEUNG, M. W., LEUNG, V., VAN DER VELDE, G. & KRAHN, M. 2012. Cost effectiveness of hepatitis C-related interventions targeting substance users and other high-risk groups: a systematic review. *Pharmacoeconomics*, 30, 1015-34.

KABIRI, M., JAZWINSKI, A. B., ROBERTS, M. S., SCHAEFER, A. J. & CHHATWAL, J. 2014. The changing burden of hepatitis C virus infection in the United States: model-based predictions. *Ann Intern Med*, 161, 170-80.

KAWAMURA, Y., TAKASAKI, S. & MIZOKAMI, M. 2012. Using decision tree learning to predict the responsiveness of hepatitis C patients to drug treatment. *FEBS Open Bio*, 2, 98-102.

KELTCH, B., LIN, Y. & BAYRAK, C. 2014. Comparison of AI techniques for prediction of liver fibrosis in hepatitis patients. *J Med Syst*, 38, 60.

KHATRI, N., LATHER, V. & MADAN, A. K. 2015. Diverse models for anti-HIV activity of purine nucleoside analogs. *Chem Cent J*, 9, 29.

KIM, W. R., POTERUCHA, J. J. & GROSS, J. B., JR. 2000. Cost-effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C. *Hepatology*, 31, 807-8.

KRAHN, M., WONG, J. B., HEATHCOTE, J., SCULLY, L. & SEEFF, L. 2004. Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990. *Med Decis Making*, 24, 20-9.

KUROSAKI, M., HIRAMATSU, N., SAKAMOTO, M., SUZUKI, Y., IWASAKI, M., TAMORI, A., MATSUURA, K., KAKINUMA, S., SUGAUCHI, F., SAKAMOTO, N., NAKAGAWA, M. & IZUMI, N. 2012. Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C. *J Hepatol*, 56, 602-8.

- LOUBIERE, S., ROTILY, M. & MOATTI, J. P. 2000. [Medico-economic assessment of the therapeutic management of patients with hepatitis C]. *Gastroenterol Clin Biol*, 24, 1047-51.
- LOUBIERE, S., ROTILY, M. & MOATTI, J. P. 2002. Appraisal of economic evaluations of treatments and screening for hepatitis C. *Med Sci (Paris)*, 18, 325-333.
- MANNIS, M. P. 2004. Adherence to combination therapy: influence on sustained virologic response and economic impact. *Gastroenterol Clin North Am*, 33, S11-24.
- MARCELLUSI, A., VITI, R., CAPONE, A. & MENNINI, F. S. 2014. [Cost of illness probabilistic methodology to assess direct and indirect costs of HCV-related disease in Italy]. *Pharmacoeconomics Italian Research Articles*, 16, 23.
- MARTIN, N. K., VICKERMAN, P., MINERS, A. & HICKMAN, M. 2013. How cost-effective is hepatitis C virus treatment for people who inject drugs? *J Gastroenterol Hepatol*, 28, 590-2.
- MYERS, R. P., KRAJDEN, M., BILODEAU, M., KAITA, K., MAROTTA, P., PELTEKIAN, K., RAMJI, A., ESTES, C., RAZAVI, H. & SHERMAN, M. 2014. Burden of disease and cost of chronic hepatitis C infection in Canada. *Can J Gastroenterol Hepatol*, 28, 243-50.
- NEOH, C. F. & KONG, D. C. 2014. The cost-effectiveness of boceprevir for hepatitis C. *Expert Rev Pharmacoecon Outcomes Res*, 14, 319-34.
- ORLEWSKA, E. 2004. Cost-effectiveness of pegylated IFN-alpha2b and -2a and ribavirin for chronic hepatitis C treatment. *Expert Rev Pharmacoecon Outcomes Res*, 4, 495-504.
- RUGER, J. P., ABDALLAH, A. B., NG, N. Y., LUEKENS, C. & COTTLER, L. 2014. Cost-effectiveness of interventions to prevent HIV and STDs among women: a randomized controlled trial. *AIDS Behav*, 18, 1913-23.
- SHERMOCK, K. M., TEMPLE, M. E. & YOUNOSSI, Z. M. 2002. The cost-effectiveness of treating chronic hepatitis C. *Drug Benefit Trends*.
- SPAULDING, A. S., KIM, A. Y., HARZKE, A. J., SULLIVAN, J. C., LINAS, B. P., BREWER, A., DICKERT, J., MCGOVERN, B. H., STRICK, L. B., TRESTMAN, R. & FERGUSON, W. J. 2013. Impact of new therapeutics for hepatitis C virus infection in incarcerated populations. *Top Antivir Med*, 21, 27-35.
- TANAKA, J., KUMADA, H., IKEDA, K., CHAYAMA, K., MIZUI, M., HINO, K., KATAYAMA, K., KUMAGAI, J., KOMIYA, Y., MIYAKAWA, Y. & YOSHIZAWA, H. 2003. Natural histories of hepatitis C virus infection in men and women simulated by the Markov model. *J Med Virol*, 70, 378-86.
- THORLUND, K., DRUYTS, E., EL KHOURY, A. C. & MILLS, E. J. 2012. Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection. *Clinicoecon Outcomes Res*, 4, 349-59.
- TRAYNOR, K. 2014. Effectiveness, costs weigh on HCV treatment decisions. *Am J Health Syst Pharm*, 71, 1156-7.
- TSOCHATZIS, E. A., CROSSAN, C. & LONGWORTH, L. 2014. Cost-effectiveness of upcoming treatments for hepatitis C: we need to get the models right. *J Hepatol*, 61, 453-4.

YI, Q., WANG, P. P. & KRAHN, M. 2004. Improving the accuracy of long-term prognostic estimates in hepatitis C virus infection. *J Viral Hepat*, 11, 166-74.

**Reason for exclusion, abstract only (n=121)**

AHMED, A., GORDON, S. C., SAAB, S. & YOUNOSSI, Z. 2014. Evaluation of the health outcomes for ledipasvir/ sofosbuvir in early vs. Delayed treatment according to fibrosis stage of patients with chronic hepatitis C virus (HCV) genotype 1 infection: Results from a decision-analytic markov model. *Hepatology*, 60, 1041A.

ALMADIYEVA, A., KOSTYUK, A. & NURGOZHIN, T. 2013. Comparative effectiveness of triple therapy versus dual therapy for chronic hepatitis C virus infection in Kazakhstan. *Value in Health*, 16, A345.

AREIAS, J., BRANCO, T., CALINAS, F., CARVALHO, A., MACEDO, G., MANATA, M. J., MATOS, L., RODRIGUES, B., VELOSA, J., PEREIRA, C., SANCHES, M. & RUBIO-TERRES, C. 2011. Treatment of chronic hepatitis C patients with peginterferon alfa-2a or peginterferon alfa-2b: A cost-effectiveness analysis for the Portuguese NHS setting. *Value in Health*, 14, A394-A395.

ATHANASAKIS, K., KARAMPLI, E., RETSA, M. P., THEODOROPOULOU, T. & KYRIOPOULOS, J. 2013. Cost effectiveness analysis of boceprevir (BOC) added to pegifn/ ribavirin (p/r) versus pegifn/ribavirin (current standard of care) for the treatment of patients with genotype 1 chronic hepatitis C in Greece. *Value in Health*, 16, A352.

BARROS, F. M. R., CHEINQUER, H., BORGES, L. G. & SANTOS, E. 2010. Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with genotype 1 chronic hepatitis C under the public payer perspective in Brazil. *Value in Health*, 13, A72.

BARROS, F. M. R., CHEINQUER, H., BORGES, L. G. & SANTOS, E. 2010. Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with genotypes 2/3 chronic hepatitis C under the public payer perspective in Brazil. *Value in Health*, 13, A71-A72.

BECKER, B., CHHATWAL, J., FERRANTE, S., ELBASHA, E. H. & KROBOT, K. J. 2012. Cost-effectiveness of boceprevir-based treatment of chronic genotype 1 hepatitis C virus (HCV) infection from the perspective of the German statutory health insurance (SHI). *Value in Health*, 15, A392.

BECKER, B., CHHATWAL, J., FERRANTE, S., ELBASHA, E. H. & KROBOT, K. J. 2012. Projecting the clinical impact of treating hepatitis C genotype 1 infection with boceprevir in Germany. *Value in Health*, 15, A387.

BLATT, C. R., STORB, B. H., MUHLBERGER, N., WURM, J., FARIAS, M. R. & SIEBERT, U. 2011. Chronic hepatitis C treatment for genotype 2 or 3: Cost-effectiveness analysis of PEG as first line treatment with the Brazilian protocol. *Value in Health*, 14, A540.

BROGAN, A., MILLER, J., TALBIRD, S., THOMPSON, J. & DENIZ, B. 2011. Cost-effectiveness assessment of telaprevir combination treatment compared to pegylated-interferon+ribavirin alone in the management of chronic hepatitis C in treatment-naive patients. *American Journal of Gastroenterology*, 106, S410.

BROGAN, A., TALBIRD, S. E., THOMPSON, J. R., MILLER, J. D., GEORGE, S. & HVIDSTEN, K. 2012. Cost-effectiveness of first-line versus second-line telaprevir

combination treatment in the management of chronic hepatitis c virus infection for treatment-naive patients with IL28B genotype CC. *Gastroenterology*, 142, S173.

BROGAN, A. J., MILLER, J. D., TALBIRD, S. E., THOMPSON, J. R. & DENIZ, B. 2011. Long-term clinical value of telaprevir for treatment of treatment-naive and treatment-experienced patients with hepatitis C virus (HCV) infection: Projections using decision-analytic modeling. *Gastroenterology*, 140, S947.

BUTI, M., GROS, B., OYAGUEZ, I., ANDRADE, R. J., SERRA, M. A., TURNES, J. & CASADO, M. A. 2013. Cost-effectiveness analysis of telaprevir triple therapy for treatment-naive patients with chronic hepatitis C based on the combined efficacy data of the ADVANCE and OPTIMIZE studies. *Hepatology*, 58, 1133A.

CANAVAN, C., COREY, K. & HUR, C. 2013. Defining cirrhosis with fibroscan for entry to hepatocellular carcinoma surveillance in chronic hepatitis C: A UK cost effectiveness analysis. *Gut*, 62, A35.

CARLOS, F. & DE, H. 2010. Cost-effectiveness of peginterferon alpha-2a plus ribavirin for treating chronic hepatitis c virus infection compared with no treatment in Mexico. *Value in Health*, 13, A439.

CARLOS, F. & DEHESA 2010. Cost-effectiveness of peginterferon alpha-2a versus peginterferon alpha-2b for treatment of chronic hepatitis c infection in Mexico. *Value in Health*, 13, A439.

CHAN, K., LAI, M. N., GROESSL, E. J., HANCHATE, A., HERNANDEZ, L., WONG, J. B., CLARK, J. A., ASCH, S., GIFFORD, A. L. & HO, S. 2011. Potential costs associated with new direct acting antiviral (DAA) therapy for untreated chronic hepatitis C genotype 1 infection in the veterans health administration. *Value in Health*, 14, A269-A270.

CHAN, K., LAI, M. N., GROESSL, E. J., HANCHATE, A. D., HERNANDEZ, L., WONG, J. B., CLARK, J., ASCH, S., GIFFORD, A. L. & HO, S. B. 2011. Long term clinical impact of direct antiviral agent (DAA) therapy for untreated chronic hepatitis C genotype 1 infection in the veterans health administration. *Hepatology*, 54, 437A-438A.

CHEN, W. & WEI, L. 2011. Cost-effectiveness analysis of peg-interferon alpha-2a plus ribavirin versus conventional interferon alpha-2a plus ribavirin for the treatment of chronic hepatitis C in China. *Value in Health*, 14, A280.

CHHATWAL, J., CHOPRA, K. B., ROBERTS, M. S. & DUNN, M. A. 2013. Framework for determining the cost-effectiveness of new antiviral agents for hepatitis c. *Hepatology*, 58, 386A-387A.

CHHATWAL, J., DUNN, M. A., ROBERTS, M. S. & CHOPRA, K. B. 2012. Prioritization of hepatitis C patients for treatment with direct acting antiviral agents. *Hepatology*, 56, 268A-269A.

CHHATWAL, J., FERRANTE, S. A., DASBACH, E. J., EL KHOURY, A., BRASS, C. A., BURROUGHS, M., BACON, B. R., ESTEBAN, R. & ELBASHA, E. 2011. Cost-effectiveness of boceprevir use in patients with chronic hepatitis C genotype-1 who failed prior treatment with peginterferon/ ribavirin. *Hepatology*, 54, 801A-802A.

CHHATWAL, J., FERRANTE, S. A., DASBACH, E. J., EL KHOURY, A., BURROUGHS, M., BACON, B., ESTEBAN-MUR, R. & BRASS, C. 2011. Projecting the

long-term clinical impact of Boceprevir in patients with chronic hepatitis C genotype-1 who failed prior treatment with Peginterferon/ribavirin. *Journal of Hepatology*, 54, S164.

CHHATWAL, J., FERRANTE, S. A., DASBACH, E. J., EL KHOURY, A., BURROUGHS, M., BACON, B. R., ESTEBAN, R. & BRASS, C. A. 2011. Projecting the long-term clinical impact of boceprevir in patients with chronic hepatitis C genotype-1 who failed prior treatment with peginterferon/ribavirin. *Gastroenterology*, 140, S947.

CHHATWAL, J., KANWAL, F., ROBERTS, M. S. & DUNN, M. A. 2014. The economic impact of sofosbuvir-and simeprevir-based HCV treatment in the United States. *Hepatology*, 60, 255A-256A.

CHHATWAL, J., LUNDBERG, J., FERRANTE, S., EL KHOURHY, A. C., OKSANEN, A. & ELBASHA, E. H. 2012. Cost-effectiveness of boceprevir in the treatment of chronic Hepatitis c genotype 1 in Sweden. *Journal of Hepatology*, 56, S386-S387.

CHIDI, A. P., ROGAL, S. S., BRYCE, C. L., FINE, M. J., GOOD, C. B., MYASKOVSKY, L., RUSTGI, V. K., TSUNG, A. & SMITH, K. J. 2014. Cost-effectiveness of novel hepatitis C drug regimens among treatment-experienced U.S. veterans. *Hepatology*, 60, 234A.

COOPER, K., BAXTER, L., LOVEMAN, E., HARTWELL, D. & FRAMPTON, G. 2013. The cost effectiveness of peginterferon alfa and ribavirin for the treatment of hepatitis c in children and young people. *Value in Health*, 16, A499.

CORTESI, P. A., CIACCIO, A., ROTA, M., DE SALVIA, S., OKOLICSANYI, S., VINCI, M., BELLI, L. S., LIM, J. K., MANTOVANI, L. G. & STRAZZABOSCO, M. 2014. Management of chronic hepatitis C (CHC) genotype 1 treatment-naive patients in an era of rising opportunities and costs: A cost-effectiveness analysis. *Digestive and Liver Disease*, 46, e11.

CORTESI, P. A., CIACCIO, A., ROTA, M., DE SALVIA, S., VINCI, M., BELLI, L. S., LIM, J. K., MANTOVANI, L. G. & STRAZZABOSCO, M. 2014. Management of chronic hepatitis C (CHC) genotype 1 treatment-naive patients in an era of rising opportunities and costs-a cost-effectiveness analysis of treatment options. *Journal of Hepatology*, 60, S493.

CURE, S., BIANIC, F., CAWSTON, H., CAWSTON, L. & ZHANG, F. 2010. Impact of sustained virological response (SVR) on life expectancy and quality-adjusted life-years (QALYs) in chronic hepatitis C (CHC) patients. *Journal of Hepatology*, 52, S421.

CURE, S., BIANIC, F., CAWSTON, H., DARTOIS, L. & ZHANG, H. 2010. Estimated impact of sustained virological response (SVR) on life expectancy, quality-adjusted life-years (QALYS) and lifetime costs in chronic hepatitis c (CHC) patients. *Value in Health*, 13, A430.

CURE, S., BIANIC, F., DARTOIS, L., CAWSTON, H. & ZHANG, H. 2010. Impact of sustained virological response (SVR) on life expectancy and quality-adjusted life-years (QALYS) in chronic hepatitis C (CHC) patients. *Value in Health*, 13, A187.

CURE, S., CURTIS, S., BIANIC, F., GAVART, S., DEARDEN, L., FLEISCHMANN, J., OUWENS, M. & LEE, S. 2012. The cost-effectiveness of telaprevir (TVR) in combination with pegylated interferon-alfa and ribavirin (PR) for the treatment of genotype 1(G1) chronic Hepatitis C patients. *Value in Health*, 15, A241-A242.



- CURE, S. & GUERRA, I. 2014. Cost-effectiveness and long-term outcomes of Sovaldi (sofosbuvir) for the treatment of chronic hepatitis c infected (HCV) patients from a Swedish societal perspective. *Value in Health*, 17, A675.
- CURRY, M. P. & BLEIBEL, W. 2012. Update on the treatment of hepatitis C genotype 1. *Journal of Clinical Outcomes Management*, 19, 422-431.
- CURTIS, S., CURE, S., BIANIC, F., GAVART, S., DEARDEN, L., FLEISCHMANN, J., OUWENS, M. & LEE, S. 2012. The cost-effectiveness of telaprevir (TVR) in Combination with pegylated interferon-alfa and ribavirin (PR) for the treatment of Genotype 1(G1) chronic hepatitis c patients: A post-hoc analysis of IL-28B subgroup. *Value in Health*, 15, A244-A245.
- CURTIS, S., CURE, S., GAVART, S., DEARDEN, L., FLEISCHMANN, J., OUWENS, M. & LEE, S. 2012. The cost-effectiveness of telaprevir (TVR) in combination with pegylated interferon-alfa and ribavirin (PR) for the treatment of genotype 1 chronic hepatitis C patients. *Journal of Hepatology*, 56, S434.
- DAN, Y. Y., FERRANTE, S. A., ELBASHA, E. H., CHHATWAL, J., ZHANG, X. H. & HSU, T. Y. 2013. Disease progression and cost-effectiveness for chronic hepatitis C virus genotype1: Boceprevir usage with singapore setting. *Hepatology International*, 7, S432.
- D'ANGELO, E. R., GARCIA GONZALEZ, I. & SIMON, M. A. 2012. The use of futility rules in economic evaluations with direct acting agents (daa) in the treatment of genotype 1 hepatitis c virus (HCV) from a spanish health care perspective. *Value in Health*, 15, A392-A393.
- DE LEDINGHEN, V., ORSINI, M., FOUCHER, J., VERGNIOL, J., CHERMAK, F., MESSAOUDI, N. & DAURES, J. P. 2012. Cost-effectiveness of HCV treatment in genotype 1 naive patients in 2012. *Journal of Hepatology*, 56, S384-S385.
- DENIZ, B., BROGAN, A., MILLER, J., TALBIRD, S. & THOMPSON, J. 2011. Cost-effectiveness assessment of telaprevir combination treatment compared to pegylated-interferon+ribavirin alone in the management of hepatitis c in patients who failed prior pegylated-interferon+ribavirin treatment 2011 acg presidential poster. *American Journal of Gastroenterology*, 106, S410.
- EKSTROM, V. S. M., YEE, M. L., CHOW, W. C. & KUMAR, R. 2015. Cost effectiveness of pegylated inteferon and ribavirin combination in treating genotype 1 hepatitis C patients in Singapore. *Hepatology International*, 9, S268.
- JALUNDHWALA, Y. J., MANZOOR, B. S., PATEL, H., CHENG, W. H., PATEL, P. & TOUCHETTE, D. R. 2014. Cost-effectiveness of pharmacotherapies for treatment naive hepatitis C genotype 1 patients: A payer's perspective. *Value in Health*, 17, A273.
- JALUNDHWALA, Y. J., PATEL, P., NANCY, H., WENDY, C., BEENISH, M., HARIDARSHAN, P. & TOUCHETTE, D. 2012. Evaluating the cost-effectiveness of using boceprevir and telaprevir in the treatment of newly diagnosed Hepatitis C genotype 1 patients: A payer's perspective. *Pharmacotherapy*, 32, e300-e301.
- KANG, J., BARON, K., POLHAMUS, D., FRENCH, J. L. & GASTONGUAY, M. R. 2013. Model-based meta-analysis for virologic response rate in hepatitis C virus (HCV) clinical trials. *Clinical Pharmacology and Therapeutics*, 93, S5.

KHAIRY, A. M., AWAD, A., EL-AKEL, W., DOSS, W., ZAYED, N. & MABROUK, M. 2012. Using data mining techniques to predict sustained virological response in Egyptian patients with chronic Hepatitis C Virus. *Journal of Gastroenterology and Hepatology*, 27, 251-252.

KUROSAKI, M., SAKAMOTO, N., IWASAKI, M., SAKAMOTO, M., SUZUKI, Y., HIRAMATSU, N., SUGAUCHI, F., SATO, M., TSUCHIYA, K., ASAHINA, Y. & IZUMI, N. 2010. Impact of mutations in ISDR and core region of HCV on pretreatment prediction of sustained virological response to pegylated-interferon plus ribavirin therapy revealed by classification and regression tree analysis. *Hepatology International*, 4, 190-191.

LA TORRE, G., MIELE, L., MANNOCCI, A., SAULLE, R., GIRALDI, G., UNIM, B., URSILLO, P., SEMYONOV, L., COLAMESTA, V., MELCARNE, R., BIOLATO, M., CECCHI, R., VILLARI, P. & DE GIUSTI, M. 2013. Organizational and economic issues related to the introduction of boceprevir in the treatment of patients with genotype 1 chronic hepatitis C in Italy. *Value in Health*, 16, A494-A495.

LAI, M. N., CHAN, K., GROESSL, E. J. & HO, S. B. 2013. Long term clinical impacts of interferon-free direct antiviral agent therapy for chronic hepatitis C genotype 1 infection in the Veterans Health Administration. *Hepatology*, 58, 1165A.

LECHUGA, D. & ALVA, M. 2012. Economic evaluation of the use of peg-interferon alfa 2a in the treatment of patients with chronic hepatitis C public Mexican perspective. *Value in Health*, 15, A136-A137.

LION, M., MCCANN, E. & JIANG, Y. 2013. Cost-effectiveness of peginterferon alfa and ribavirin for the treatment of children and young people with chronic hepatitis C from the perspective of the NHS in England and Wales. *Value in Health*, 16, A352.

LUKAC, M., BIELIK, J., HOLOMAN, J., TOMEK, D., SUVADOVA, A., FOLTANOVA, T. & FOLTAN, V. 2012. Cost-utility analysis of telaprevir in combination with peginterferon alpha and ribavirin in previously treated patients with chronic hepatitis C. *Value in Health*, 15, A330.

MACIOCH, T., PAWESKA, J., NIEWADA, M., BERAK, H., SZKULTECKA-DEBEK, M. & RUSSEL-SZYMCZYK, M. 2011. Cost-effectiveness analysis of pegylated interferon alpha-2A versus pegylated interferon alpha-2b in the treatment of chronic hepatitis C patients in Poland. *Value in Health*, 14, A274-A275.

MAO, W. H., CHEN, W. & WEI, L. 2014. Economic evaluation of viral load test (VLT) in response guided treatment (RGT) for chronic hepatitis C (CHC). *Value in Health*, 17, A749-A750.

MARCELLUSI, A., VITI, R., CAPONE, A. & MENNINI, F. S. 2014. Direct and indirect cost of HCV-related diseases in Italy: An incidence-based probabilistic approach. *Value in Health*, 17, A671.

MCDERMOTT, C. L., VEENSTRA, D. L., HANSEN, R. N. & SULLIVAN, S. D. 2013. The value of improving treatment adherence in chronic hepatitis C infection. *Value in Health*, 16, A214.

MCEWAN, P., WARD, T., KIM, R., L'ITALIEN, G. & YUAN, Y. 2013. Validation of the monarch hepatitis C model to Japanese hepatocellular carcinoma incidence data. *Hepatology International*, 7, S730-S731.

MCEWAN, P., WARD, T., YUAN, Y. & L'ITALIEN, G. 2013. Assessing the importance of fibrosis stage on the cost-effectiveness of birth-cohort versus risk-based screening and treatment for hepatitis c virus infection. *Value in Health*, 16, A186.

MCEWAN, P., YUAN, Y. & KIM, R. 2010. A need for a dynamic approach to modelling disease progression in cost-effectiveness studies of antiviral therapies in patients with Chronic Hepatitis C. *Hepatology International*, 4, 197.

MCEWAN, P., YUAN, Y. & KIM, R. 2012. Evaluating optimal treatment outcomes of antiviral therapy in Hepatitis C for prior null responders in the era of first generation protease inhibitors. *Journal of Hepatology*, 56, S387.

MCEWAN, P., YUAN, Y., LITALIEN, G. & KIM, R. 2011. Cost benefit analysis of response guided therapy: Dynamic disease Markov modeling for patients with chronic hepatitis (HCV) by fibrosis stages. *Journal of Hepatology*, 54, S461.

MCEWAN, P., YUAN, Y., TOWNSEND, R. & KIM, R. W. 2010. The impact of age dependent utility on the cost effectiveness of pegylated interferon and ribavirin versus interferon and ribavirin as therapy for genotype 1 patients with chronic hepatitis C. *Value in Health*, 13, A193.

MCGHAN, A. A. & KAPLAN, D. E. 2012. Costs of palliative treatments of intermediate and advanced stage hepatocellular carcinoma may exceed usually accepted limits of cost effectiveness. *Hepatology*, 56, 1097A.

MCGINNIS, J. J. & HAY, J. W. 2014. The cost-effectiveness of hepatitis C treatments in treatment naive genotype 1 patients. *Value in Health*, 17, A274-A275.

MERNAGH, P., FENG, J. & DEL CUORE, M. 2013. Cost-effectiveness of boceprevir therapy in adult patients with chronic hepatitis C (HCV) genotype 1. *Value in Health*, 16, A94.

MERNAGH, P., FENG, J. & DEL CUORE, M. 2013. Cost-effectiveness of boceprevir therapy in previously treated adult patients with chronic hepatitis C (HCV) genotype 1. *Hepatology International*, 7, S392.

MERNAGH, P., FENG, J. & DEL CUORE, M. 2013. Cost-effectiveness of boceprevir therapy in untreated adult patients with chronic hepatitis C (HCV) genotype 1. *Hepatology International*, 7, S391.

MERNAGH, P., NORRIS, S. & DEL CUORE, M. 2011. Anti-viral treatment of chronic hepatitis C in a paediatric population: A cost-effectiveness analysis. *Value in Health*, 14, A403.

MORAIS, A. D. & PEREIRA, M. L. 2013. Cost-effectiveness of telaprevir plus peginterferon/riba virin (TVR+PR) versus peginterferon/riba virin (PR) in treatment-naive genotype 1 chronic hepatitis patients with f2 fibrosis in Brazil. *Value in Health*, 16, A354.

MOURAD, A., DEUFFIC-BURBAN, S., RENAULT-VANTROYS, T., GANNE-CARRIE, N., ROSA, I., BOUVIER, A. M., LAUNOY, G., CATTAN, S., LOUVET, A., DHARANCY, S., TRINCHET, J. C., YAZDANPANA, Y. & MATHURIN, P. 2013. Ultrasonographic (US) screening of hepatocellular carcinoma (HCC) in compensated cirrhosis due to hepatitis C virus (HCV) improves survival: A modeling approach. *Journal of Hepatology*, 58, S269.

NIKOGLOU, E., HUMPHREYS, S., EL KHOURY, A., FERRANTE, S. A. & O'REGAN, C. 2011. The clinical efficacy and cost-effectiveness of boceprevir in combination with pegylated interferon-alfa and ribavirin for the treatment of genotype 1 chronic hepatitis C patients: A within trial analysis from the perspective of the scottish national health service (NHS). *Value in Health*, 14, A274.

NORRIS, S., CAMPBELL, S., RADALJ, L., ELLIOTT, L. & DUNLOP, S. L. 2009. Cost effectiveness of pegylated-interferon alpha 2B + ribavirin for chronic hepatitis C (CHC) In patients who have previously failed treatment with interferon-based therapy in Australia. *Value in Health*, 12, A424.

NORTHUP, P. G., AL-OSAIMI, A. M., CALDWELL, S. H. & ARGO, C. K. 2009. Cost effectiveness of STAT-C agents in treating genotype 1 chronic hepatitis C. *Hepatology*, 50, 671A.

NOVAK, A., DRENTH, J. P. H. & DE KNEGT, R. J. 2014. Costs per successfully treated patient with sofosbuvir in GT1 HCV. *Value in Health*, 17, A673.

NOVAK, A., DRENTH, J. P. H. & DE KNEGT, R. J. 2014. The pan-genotypic costs-effectiveness of sofosbuvir in hepatitis c virus. *Value in Health*, 17, A676.

OBACH, D., YAZDANPANA, Y., ESMAT, G. E., CANVA-DELCAMBRE, V., DEWEDAR, S., ANWAR, W. A., DOSS, W. H., MOSTAFA, A., POL, S., BUTI, M., SIEBERT, U., FONTANET, A., MOHAMED, M. K. & DEUFFIC-BURBAN, S. 2012. Impact of different treatment scale-up and eligibility scenarios on HCV mortality in egypt in the next five years. *Hepatology*, 56, 1012A.

ODHIAMBO, R., CHHATWAL, J., FERRANTE, S. A., EL KHOURY, A. & ELBASHA, E. 2012. Economic evaluation of boceprevir for the treatment of patients with genotype 1 chronic hepatitis C virus infection in hungary. *Value in Health*, 15, A390.

OMELYANOVSKY, V. V., AVKSENTIEVA, M. V., KRYSANOV, I. & IVAKHNENKO, O. 2010. Cost-effectiveness analysis of peginterferon (ALFA-2B) with ribavirin compared with peginterferon (ALFA-2A) with ribavirin for the treatment of chronic hepatitis c. *Value in Health*, 13, A431.

OZDEMIR, O. 2014. The cost-effectiveness of telaprevir triple therapy in treatment of naive chronic hepatitis c patients in Turkey. *Value in Health*, 17, A670.

PAPATHEODORIDIS, G. V. & ARZOUMANIDOU, D. 2012. Cost-effectiveness analysis of different protease inhibitors-based strategies in the treatment of naive patients with genotype 1 chronic hepatitis C (G1-CHC). *Hepatology*, 56, 1014A.

PAREKH, H., MCGARRY, L., PAWAR, V., DENIZ, B. & WEINSTEIN, M. 2011. Projected lifetime economic burden of hepatitis C virus in U.S. Birth cohorts with high prevalence. *Journal of Managed Care Pharmacy*, 17, 567-568.

PARRONDO, J., RINCON RODRIGUEZ, D., ROMERO GOMEZ, M., SOLA LAMOGLIA, R. & ROLDAN, C. 2014. Cost-effectiveness analysis of eltrombopag as support treatment in chronic HCV infected patients with thrombocytopenia to enable interferon-based regimens. *Value in Health*, 17, A532.

PAVELIU, M. S., COMSA, R. & MIRCEA, R. 2013. Cost-utility analysis of telaprevir in combination with peginterferon alpha and ribavirin in previously untreated patients with chronic hepatitis in a romanian setting. *Value in Health*, 16, A499.

- PIRATVISUTH, T., PRAMOOLSINSAP, C., CHUTAPUTTI, A., TANWANDEE, T., THONGSAWAT, S., SUKAROM, I., TINMANEE, S. & BERGER, W. 2009. Cost-effectiveness analysis of peginterferon alfa-2a (40 KD) plus ribavirin versus no treatment in patients with chronic hepatitis C (CHC), genotype 1 from a payer perspective in Thailand. *Hepatology*, 50, 714A-715A.
- PYADUSHKINA, E., AVXENTYEVA, M., OMELYANOVSKY, V. V., TREUR, M. & WESTERHOUT, K. Y. 2014. Cost-effectiveness analysis of antiviral pharmacotherapies for treatment of chronic hepatitis C virus infection in Russia. *Value in Health*, 17, A366-A367.
- RAMACHANDRAN, S., MAHABALESHWARKAR, R. & YANG, Y. 2012. Cost effectiveness analysis of addition of telaprevir or boceprevir to standard therapy versus standard therapy alone for the treatment of previously untreated chronic Hepatitis-C virus genotype 1 infection. *Value in Health*, 15, A242.
- REIN, D. B. 2013. A review and summary analysis of major studies of the cost-effectiveness birth cohort testing for hepatitis c in United States. *Hepatology*, 58, 391A.
- REIN, D. B., WITTENBORN, J. S., LIFFMANN, D. K., HASCHE, J. C., BORTON, J. M., KRAMER, J. R., DUAN, Z. & EL-SERAG, H. B. 2014. Projected health and economic impact of hepatitis c on the united states veterans administration health system from 2014 to 2024. *Journal of Hepatology*, 60, S332.
- RUGGERI, M. 2014. Using bayesian modelling to estimate the cost effectiveness of telaprevir and boceprevir in Italian naive patients with hepatitis C. *Value in Health*, 17, A277.
- RYAZHENOV, V. V., SBOYEVA, S. G. & EMCHENKO, I. V. 2013. Pharmacoeconomic analysis of different antiviral therapies in the treatment of Russian patients with chronic hepatitis c. *Value in Health*, 16, A345.
- SAAB, S., GORDON, S. C., PARK, H., AHMED, A. & YOUNOSSI, Z. M. 2014. A decision analytic markov model to evaluate the health outcomes of sofosbuvir for previously untreated patients and those without treatment options with chronic hepatitis C virus. *Gastroenterology*, 146, S-912.
- SAID, M., DRAGOSITS, A. & WALTER, E. 2012. Cost-effectiveness-analysis of the combination-therapy telaprevir, peg-ifn+2a and ribavirin in patients with chronic hepatitis-C in austria. *Value in Health*, 15, A392.
- SALINAS ESCUDERO, G., IDROVO, J., RIVAS, R., RAMIREZ RODRIGUEZ, J., RICO ALBA, I. A. & ZAPATA, L. 2009. Cost-effectiveness of peg-ifn alpha 2A OR 2B plus ribavirin in the treatment of chronic hepatitis C in Mexico. *Value in Health*, 12, A59.
- SALINAS ESCUDERO, G., IDROVO, J., RIVAS, R., RAMIREZ RODRIGUEZ, J., RICO ALBA, I. A. & ZAPATA, L. 2009. Cost-effectiveness of PEG-IFN alpha 2A OR 2B plus ribavirin in the treatment of chronic hepatitis C in Mexico. *Value in Health*, 12, A508.
- SIEBERT, U., MUHLBERGER, N., CONRADS-FRANCENK, A., SROCZYNSKI, G. & SCHWARZER, R. 2009. Using Iqwig's efficiency frontier approach for the economic evaluation of hepatitis c treatment - a pilot and feasibility study commissioned by IQWIG. *Value in Health*, 12, A225.
- SILVA, M., FELIX, J., FERREIRA, D., VANDEWALLE, B., GUERRA, I., CURE, S., ALDIR, I., CARVALHO, A., MACEDO, G., MARINHO, R. T., PEDROTO, I. &

- RAMALHO, F. 2014. Sofosbuvir for the treatment of chronic hepatitis C: A comprehensive cost-effectiveness analysis across hcv genotypes, pretreatment conditions and HIV co-infection. *Value in Health*, 17, A366.
- STAHMEYER, J. T., SCHAUER, S., WIRTH, D., FLEISCHMANN, J., LEE, S., GAVART, S., BIANIC, F., CURE, S. & KRAUTH, C. 2012. Cost-effectiveness of triple therapy with telaprevir for the treatment of treatment-naive genotype 1 chronic hepatitis c patients in germany. *Value in Health*, 15, A396.
- SYPSA, V., MAGIORKINIS, G., MAGIORKINIS, E., PARASKEVIS, D., KATSOULIDOU, A. S., PAPTAEODORIDIS, G. V. & HATZAKIS, A. 2012. The impact of primary prevention and treatment as prevention in controlling the epidemic of hepatitis C under the new therapeutic options. *Hepatology*, 56, 1051A.
- TAN, S. S., FERRANTE, S. A., ELBASHA, E. H., CHHATWAL, J., OMAR, H., KIEW, K. K., HASSAN, M. R. A., MENON, J. & HSU, T. Y. 2013. The cost-effectiveness of boceprevir based triple therapy for genotype 1 hepatitis C in the settings of malaysia's public sector healthcare. *Hepatology International*, 7, S723-S724.
- THONGSAWAT, S., PIRATVISUTH, T., PRAMOOLSINSAP, C., CHUTAPUTTI, A., TANWANDEE, T., BERGER, W., SUKAROM, I. & TINMANEE, S. 2009. Peginterferon alfa-2a (40kd) plus ribavirin is dominant with large cost-savings versus no treatment in patients with chronic hepatitis C (CHC), genotype 2/3: A cost-effectiveness analysis from the Thai payer perspective. *Hepatology*, 50, 704A-705A.
- TSOCHATZIS, E., CROSSAN, C., LONGWORTH, L., GURUSAMY, K., RODRIGUEZ-PERALVAREZ, M., MANTZOUKIS, K., O'BRIEN, J., THALASSINOS, E., PAPASTERGIOU, V., NOEL-STORR, A., DAVIDSON, B. & BURROUGHS, A. 2014. Cost-effectiveness of non-invasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis c: Systematic review and economic evaluation. *Journal of Hepatology*, 60, S33.
- VELLOPOULOU, K., VAN AGTHOVEN, M., VAN DER KOLK, A., LAMOTTE, M., CURE, S. & BIANIC, F. 2012. The cost-utility of telaprevir in combination with peginterfeon alpha and ribavirin (pr) as compared to the combination boceprevir with pr and to pr alone in the management of chronic hepatitis c in the netherlands. *Value in Health*, 15, A396.
- VENTAYOL-BOSCH, P., RUBIO-TERRES, C., GARCIA-SAMANIEGO, J., PLANAS, R., SOLA-LAMOGLIA, R., ROMERO-GOMEZ, M., DIAGO-MADRID, M., CRESPO-GARCIA, J., CALLEJA-PANERO, J. L. & TURNES-VAZQUEZ, J. 2010. Cost-effectiveness analysis of treatment of chronic hepatitis c patients with peginterferon alfa-2a or peginterferon alfa-2b both plus ribavirin in Spain. *Value in Health*, 13, A438.
- WANG, Y. D., CHEN, G. F., WU, V., WONG, A., CHAU, A., SHAO, Q., LI, F., LI, B., JI, D., LI, Z., CHEN, S. H., WANG, C. Y., NIU, X. X., DING, S., YAN, T. & LAU, G. K. K. 2015. Cost effectiveness of sofosbuvir based therapy for chronic HCV genotype 1b infection in China. *Hepatology International*, 9, S53.
- WANG, Y. D., CHEN, G. F., WU, V., WONG, A., CHAU, A., SHAO, Q., LI, F., LI, B., JI, D., LI, Z., CHEN, S. H., WANG, C. Y., NIU, X. X., DING, S. Y., YAN, T. & LAU, G. K. K. 2015. Cost effectiveness of sofosbuvir based therapy for chronic HCV genotype 1b infection in China. *Hepatology International*, 9, S47.

- WARD, T., WILTON, H. B., MCEWAN, P., KALSEKAR, A. & YUAN, Y. 2014. Assessing the health economic value of each unit of SVR improvement in HCV infection. *Hepatology*, 60, 1047A.
- WESTERHOUT, K. Y., TREUR, M. & CERRI, K. 2013. Effect of antiviral treatment rates on the predicted future burden of genotype-1 chronic hepatitis C in the United Kingdom. *Value in Health*, 16, A342.
- WONG, J. B., THORNTON, K. A., CARROLL, C. & ARORA, S. 2013. Cost-effectiveness of hepatitis C treatment by primary care providers supported by the Extension for Community Healthcare Outcomes (ECHO) Model. *Hepatology*, 58, 330A.
- WOODS, M. S., KIRI, S., LING, C., MCCRINK, L., ZIMOVETZ, E. & HASS, B. 2013. A systematic review of economic evidence in hepatitis C: An overview of cost, utility and cost-effectiveness data. *Value in Health*, 16, A349.
- WOODS, M. S., KIRI, S., LING, C., MCCRINK, L., ZIMOVETZ, E. & HASS, B. 2013. A systematic review of economic evidence in hepatitis C: Methods used in recent economic evaluations. *Value in Health*, 16, A579.
- YFANTOPOULOS, J., PAPAOUNI, K. & D'ANGELO, E. R. 2012. A cost-effectiveness analysis of telaprevir versus boceprevir in the treatment of hepatitis C: A greek national health system perspective. *Value in Health*, 15, A394.
- YOUNOSSI, Z., GORDON, S., SAAB, S., AHMED, A., PARK, H. & SULKOWSKI, M. 2014. Health and economic outcomes of sofosbuvir therapy as predicted by a markov model in the HCV/HIV co-infected cohort. *Value in Health*, 17, A37.
- YOUNOSSI, Z., SAAB, S., AHMED, A. & GORDON, S. C. 2014. A decision-analytic markov model to evaluate the health outcomes of ledipasvir/sofosbuvir (LDV/SOF) for patients with chronic hepatitis C (HCV) genotype 1 (GT1) infection. *Hepatology*, 60, 1043A.
- YOUNOSSI, Z., SINGER, M., HENRY, L., HUNT, S. L., JEFFERS, T., FROST, S. & LAM, B. P. 2014. The use of all oral regimens for treatment of chronic hepatitis C (CHC) coupled with birth cohort screening is highly cost effective: The health and economic impact on the U.S. population. *Hepatology*, 60, 256A.
- YOUNOSSI, Z. M., GORDON, S., SAAB, S., AHMED, A., CURE, S. & GUERRA, I. 2013. A decision analytic markov model to evaluate the health outcomes of sofosbuvir for previously untreated patients and those without treatment options with chronic hepatitis C virus genotype 2 infection. *Value in Health*, 16, A341.
- YOUNOSSI, Z. M., GORDON, S. C., SAAB, S., AHMED, A., BROGAN, A. & CURE, S. 2013. A decision analytic Markov model to evaluate the health outcomes of sofosbuvir for previously untreated patients with chronic hepatitis C virus genotype 1 infection. *Hepatology*, 58, 387A-388A.
- YOUNOSSI, Z. M., SAAB, S., GORDON, S. C., AHMED, A., BROGAN, A. & GUERRA, I. 2013. Evaluation of the long-term health outcomes associated with earlier versus later initiation of treatment in previously untreated patients with chronic hepatitis C virus genotype 1 infection. *Hepatology*, 58, 388A.
- YOUNOSSI, Z. M., SINGER, M. & MIR, H. M. 2013. The potential impact of interferon free oral regimens on clinical and cost outcomes of patients with chronic hepatitis C, genotype 1: A decision analytic assessment. *Journal of Hepatology*, 58, S210.

YOUNOSSI, Z. M., SINGER, M. E. & MIR, H. M. 2013. Interferon-based and interferon-free regimens for patients with chronic hepatitis c, genotype 1: Potential cost-effectiveness of biopsy-guided treatment versus treat all strategies. *Gastroenterology*, 144, S988.

ZHOU, K., FERGUSON, J., ELASHOFF, D. & SAAB, S. 2014. Treating chronic hepatitis C infection in the elderly: Estimated impact on life expectancy. *Gastroenterology*, 146, S-969.

#### **Reason for exclusion, language (n=14)**

BUTI, M. & CASADO, M. A. 2003. Cost-benefit analysis of combined therapy in chronic hepatitis C. *Enfermedades Emergentes*, 5, 90-96.

BUTI, M., CASADO, M. A., FOSBROOK, L. & ESTEBAN, E. 1998. [Cost effectiveness of the treatment of chronic hepatitis C with interferon-alpha]. 21, 161-168.

BUTI, M., CASADO, M. A., FOSBROOK, L. & ESTEBAN, R. 1998. [Cost effectiveness of the treatment of chronic hepatitis C with interferon-alpha]. *Gastroenterol Hepatol*, 21, 161-8.

BUTI, M., GROS, B., OYAGUEZ, I., ANDRADE, R. J., SERRA, M. A., TURNES, J. & CASADO, M. A. 2014. [Cost-utility analysis of triple therapy with telaprevir in treatment-naive hepatitis C patients]. 38.

CASADO GOMEZ, M. A. 2006. Cost-effectiveness of pegylated interferon-alfa in the treatment of chronic hepatitis due to HCV. *Gastroenterologia Hepatologia*, 29, 200-205.

DE MELLO VIANNA, C. M., BITTENCOURT GONZALEZ MOSEGUI, G., COSTA E SILVA, F. V., PEREGRINO, A. A. F., DA SILVA RODRIGUES, M. P. & JARDIM, F. N. 2013. Avaliação Econômica do Interferon Peguilado Alfa 2a em Combinação com a Ribavirina para o Tratamento da Infecção Pelo Genótipo 1 da Hepatite Crônica C: Comparação do Tratamento por 48 Semanas e Terapia Estendida. *Value in Health Regional Issues* 2, 342-346.

FERNANDES, F. F. 2008. Prognosis and associated factors to the effectiveness of chronic hepatitis c treatment.

GARCIA-JURADO, L., OYAGUEZ, I., CASADO, M. A., TURAL, C., GONZALEZ-GARCIA, J., ORTEGA, E. & PINEDA, J. A. 2012. [Evaluation of the costs of transient elastography (FibroScan((R))) in the diagnosis of liver fibrosis in HIV patients with hepatitis C virus]. *Enferm Infecc Microbiol Clin*, 30, 294-9.

HAIJ-SAFLO, O. & HERNANDEZ GUIJO, J. M. 2009. Cost-effectiveness of chronic hepatitis C treatment in Spain. *Gastroenterologia y Hepatologia*, 32, 472-482.

HUZICKA, I. & BIELIK, J. 2006. Economic effectivity of chronic hepatitis C (CHC) treatment by peginterferon alpha-2b and ribavarin - Slovak farmacoconomy study. *Ceska e Slovenska Gastroenterologie a Hepatologie*, 60, 83-89.

IUSHCHUK, N. D., ZNOIKO, O. O., IAKUSHECHKINA, N. A., ZYRIANOV, S. K., SHUT'KO, S. A., BELYI, P. A., KOZINA, A. N., CHAPURIN, S. A., CHURILIN, I. I. & LOUGOVSKIKH, E. A. 2013. [The burden of viral hepatitis in the Russian Federation requires reducing its progression for the long term, including chronic hepatitis C]. *Terapevticheskii Arkhiv*, 65, 79-85.



WASEM, J., SROCZYNSKI, G., AIDELSBURGER, P., BUCHBERGER, B., HESSEL, F., CONRADS-FRANK, A., PETERS-BLOCHINGER, A., KURTH, B. M., WONG, J. B., ROSSOL, S. & SIEBERT, U. 2006. [Health economics of chronic infectious diseases: the example of hepatitis C]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 49, 57-63.

YOSHIDA, H., TATEISHI, R. & OMATA, M. 2004. [Cost-effectiveness of antiviral therapy for chronic hepatitis C patients in prevention of hepatocellular cancer ]. Nihon Rinsho, 62 Suppl 7, 511-4.

ZECHMEISTER, I. & WILD, C. 2006. Chronic hepatitis C: decision analytic modelling (structured abstract). Vienna (Austria): Institute of Technology Assessment (ITA). ITA-Projektbericht 29. 2006.

**Reason for exclusion, review (n=1)**

TOWNSEND, R., MCEWAN, P., KIM, R. & YUAN, Y. 2011. Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. Value Health, 14, 1068-77.

**Reason for exclusion, duplicate (n=1)**

SHEPHERD, J., JONES, J., HARTWELL, D., DAVIDSON, P., PRICE, A. & WAUGH, N. 2007. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess, 11, 1-205, iii.

**Reason for exclusion, unobtainable (n=2)**

DORE, G. J., FREEMAN, A. J., LAW, M. & KALDOR, J. M. 2003. Natural history models for hepatitis C-related liver disease: different disease progression parameters for different settings. Antivir Ther, 8, 365-72.

KIM, D. D., HUTTON, D. W., RAOUF, A. A., SALAMA, M., HABLAS, A., SEIFELDIN, I. A. & SOLIMAN, A. S. 2012. Cost effectiveness of implementing a screening and treatment program for hepatitis C virus infection in Egypt. Cancer Research, 72.

**Reason for exclusion, no usable data (n=2)**

ARGUEDAS, M. 2004. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics, 22, 477-8; author reply 478-9.

YOUNOSSI, Z. M., HENRY, L. & SINGER, M. 2014. Reply to: "Cost-effectiveness of upcoming treatments for hepatitis C: we need to get the models right". J Hepatol, 61, 454-5.